[1]
| MCTIERNAN A, RAJAN KB, TWOROGER SS,et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol,2003,21(10): 1961–1966. doi:10.1200/JCO.2003.07.057
|
[2]
| LIEDTKE S, SCHMIDT ME, VRIELING A,et al. Postmenopausal sex hormones in relation to body fat distribution. Obesity,2012,20(5): 1088–1095. doi:10.1038/oby.2011.383
|
[3]
| SLOWIK A, FRACZEK PA, KRZEMIENIECKI K,et al. Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?. Expert Rev Anticancer Ther,2016,16(7): 759–766. doi:10.1080/14737140.2016.1191949
|
[4]
| SESTAK I, DISTLER W, FORBES JF,et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol,2010,28(21): 3411–3415. doi:10.1200/JCO.2009.27.2021
|
[5]
| GNANT M, PFEILER G, STOGER H,et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer,2013,109(3): 589–596. doi:10.1038/bjc.2013.367
|
[6]
| TAKADA M, SAJI S, MASUDA N,et al. Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast,2012,21(1): 40–45. doi:10.1016/j.breast.2011.07.015
|
[7]
| 中华人民共和国国家卫生和计划生育委员会.成人体重判断.中华人民共和国卫生行业标准, 2013, WS/T 428-2013.
|
[8]
| CARDOSO F, COSTA A, NORTON L,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast,2014,23(5): 489–492. doi:10.1016/j.breast.2014.08.009
|
[9]
| NCD Risk Factor Collaboration: trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19. 2 million participants. Lancet,2012,387(10026): 1377–1396.
|
[10]
| JIRALERSPONG S, KIM ES, DONG W,et al. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol,2013,24(10): 2506–2514. doi:10.1093/annonc/mdt224
|
[11]
| EWERTZ M, JENSEN MB, GUNNARSDOTTIR KA,et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol,2011,29(1): 25–31. doi:10.1200/JCO.2010.29.7614
|
[12]
| KYVERNITAKIS I, KNOLL D, STRUCK M,et al. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. J Cancer Res Clin Oncol,2014,140(1): 159–166. doi:10.1007/s00432-013-1557-3
|
[13]
| KAKUGAWA Y, TADA H, KAWAI M,et al. Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples. Breast Cancer Res Treat,2017,162(1): 1–11. doi:10.1007/s10549-016-4093-4
|
[14]
| MUSGROVE EA, SUTHERLAND RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer,2009,9(9): 631–643. doi:10.1038/nrc2713
|
[15]
| SIMONE V, AVENIA DM, ARGENTIERO A,et al. Obesity and breast cancer: molecular interconnections and potential clinical applications. Oncologist,2016,21(4): 404–417. doi:10.1634/theoncologist.2015-0351
|
[16]
| PFEILER G, KONIGSBERG R, FESL C,et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol,2011,29(19): 2653–2659. doi:10.1200/JCO.2010.33.2585
|
[17]
| The ATAC Trialists' group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, 2003, 98 (9): 1802-1810.
|
[18]
| WOLTERS R, SCHWENTNER L, REGIERER A,et al. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Tr,2012,131(3): 925–931. doi:10.1007/s10549-011-1874-7
|
[19]
| SENDUR MA, AKSOY S, ZENGIN N,et al. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer,2012,107(11): 1815–1819. doi:10.1038/bjc.2012.473
|
[20]
| FOLKERD EJ, DIXON JM, RENSHAW L,et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol,2012,30(24): 2977–2980. doi:10.1200/JCO.2012.42.0273
|
[21]
| BOWERS LW, CAVAZOS DA, MAXIMO IXF,et al. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Cancer Research,2013,15(4)–R59. doi:10.1186/bcr3453
|
